SOLEDUM^® 

We offer medicines with the pure natural substance cineole to treat the symptoms of inflammatory airway diseases such as common cold, bronchitis, sinusitis.

The natural active ingredient cineole removes mucus and has anti-inflammatory and laboratory proven antimicrobial effects - the small capsule with a great effect in the upper and lower airways - against the stressful symptoms in common cold, bronchitis and sinusitis.

^{(Source: https://www.umweltbundesamt.de/themen/gesundheit/umweltmedizin/copd, accessed August 2020)}

It has been proven that the power of cineole can also have a positive effect as an additional treatment for these chronic and inflammatory lung diseases.

The main cause of COPD is smoking. The symptoms are coughing with sputum and a progressive narrowing of the airways, which initially leads to shortness of breath during physical exertion and later also when at rest. Over the course of the chronic illness, disease flare-ups occur again and again (so-called exacerbations), which, depending on the severity, may have to be treated in hospital. It should not get that far in the first place. A clinical study by the University of Nuremberg-Erlangen with COPD patients has shown that the additional treatment with cineole (Soledum^®) can significantly reduce the number, severity and duration of exacerbations.

Asthma is another chronic inflammatory disease of the airways. Sudden constriction of the airways with spasms of the bronchi can occur, sometimes also with excessive mucus formation. A differentiation is made between allergic and non-allergic asthma. In a clinical study with asthma patients, during twelve-week additional treatment with cineole (3 times 200 mg per day), the corticosteroid dose of the patients could be reduced step by step under medical supervision. This result emphazises the high therapeutic benefit of the anti-inflammatory effect of cineole.

^Source

^{*National Supply Guideline Asthma 2020: Federal Medical Association, National Association of Statutory Health Insurance Physicians, Working Group of Scientific Medical Societies. Long Version, 4. Edition. Version 1. 2020 (cited 2021 May 4) DOI: 10.6101/AZQ/000469.  Available from: www.asthma.versorgungsleitlinien.de.}

^{Kehrl W et al.: Therapy for Acute Nonpurulent Rhinosinusitis With Cineole: Results of a Double-Blind, Randomized, Placebo-Controlled Trial. The Laryngoscope 2004; Vol 114 No 4: 738–742.}

^{Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial. Cough 2013, 9: 25. coughjournal.com/content/9/1/25}

^{Worth H, Dethlefsen U. Patients with Asthma Benefit from Concomitant Therapy with Cineole: A Placebo-Controlled, Double-Blind Trial. Journal of Asthma 2012; 49 (8): 849–853.}

^{Worth H et al.: Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial. Respiratory Research 2009; 10:69.}

^{Stuck BA, Popert U, Beule A et al. Rhinosinusitis S2k guideline. AWMF register no. 017/049 and 053-012. Editor: German Society for Oto-Rhino-Laryngology, Head and Neck Surgery e. V. (DGHNO-KHC), German Society for General Medicine and Family Medicine (DEGAM), Berlin. Status 04/2017. https://www.awmf.org/uploads/tx_szleitlinien/017-049_und_053-012_S2k_Rhinosinusitis_2019-04_01.pdf (accessed on: 13 August, 2020).}

^{Kardos P, Dinh QT, Fuchs K-H et al. Guideline of the German Society for Pneumology and Respiratory Medicine for the diagnosis and therapy of adult patients with cough. Pneumology 2019; 73: 143-180.}

^{Vogelmeier C, Buhl R, Burghuber O et al. Guideline for the diagnosis and treatment of patients with chronic obstructive bronchitis and pulmonary emphysema (COPD). Pneumology 2018; 72: 253-308.}